The analysis of antigenic diversity will support further development of MSP2 and CSP as vaccine candidates against malaria on two different fronts: on the one hand, by identifying fully conserved regions that can then be targeted by the host immune response, therefore conferring strain-transcending protection; and on the other hand, by informing the production of a multivalent antigen cocktail including variable domains of dozens or hundreds of clones. This evidence concerns the gene DNAJC5 and malaria.